A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

Ngoi, NYL; Heong, V; Ow, S; Chay, WY; Kim, HS; Choi, CH; Goss, G; Goh, JC; Tai, BC; Lim, DGZ; Kaliaperumal, N; Au, VB; Connolly, JE; Kim, JW; Friedlander, M; Kim, K; Tan, DSP

Tan, DSP (corresponding author), Natl Univ Singapore, Canc Sci Inst, Singapore, Singapore.; Tan, DSP (corresponding author), Natl Univ Canc Inst, Singapore, Singapore.; Tan, DSP (corresponding author), Natl Univ Hlth Syst, Singapore 119074, Singapore.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020; 30 (8): 1239

Abstract

Background The optimal treatment of recurrent ovarian clear cell carcinoma remains unknown. There is increasing rationale to support the role of immun......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索